Study on Patritumab Deruxtecan for Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have advanced non-small cell lung cancer (NSCLC) that cannot be treated with surgery or radiation.
• Cancer must have continued to grow after previous treatments, including osimertinib and at least one platinum-based chemotherapy.
• Have a specific EGFR mutation (exon 19 deletion or L858R) confirmed by tests.
• Have at least one tumor that can be measured by scans.
• Be willing to provide a tumor sample for testing.
• Be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate blood cell counts and organ function as determined by specific blood tests.

Exclusion Criteria

• Have a history of small cell lung cancer or a combination of small cell and non-small cell lung cancer.
• Have a history of lung diseases like interstitial lung disease or pulmonary fibrosis.
• Have severe breathing problems due to lung conditions or other illnesses.
• Be taking high doses of steroids or other immune-suppressing medications.
• Have cancer that has spread to the brain or spinal cord and is causing symptoms.
• Have not waited long enough after previous treatments before starting the study.
• Have previously received certain types of cancer treatments, including HER3 antibodies or topoisomerase I inhibitors.
• Have unresolved side effects from previous cancer treatments.
• Have had another active cancer within the past 3 years, except for certain non-threatening cancers.
• Have uncontrolled heart disease or active infections like hepatitis B, hepatitis C, or HIV.